statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Forecasted to Post Q1 2024 Earnings of ($0.98) Per Share

SAB Biotherapeutics, Inc. (NASDAQ:SABS - Free Report) - Equities research analysts at HC Wainwright lowered their Q1 2024 earnings per share estimates for SAB Biotherapeutics in a research note...

SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

Miami, FL , April 04, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ( SAB or the Company ), a clinical-stage biopharmaceutical company with a novel immunotherapy platform...

SAB Biotherapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

SAB Biotherapeutics ( NASDAQ:SABS ) Full Year 2023 Results Key Financial Results Net loss: US$42.2m (loss widened by...

SAB Biotherapeutics GAAP EPS of -$7.64 misses by $3.43, revenue of $2.24M beats by $1.12M

SAB Biotherapeutics GAAP EPS of -$7.64 misses by $3.43, revenue of $2.24M beats by $1.12M...

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB-142 Phase 1 trial on track for data release...

SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment

SIOUX FALLS, S.D., March 25, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ( SAB or the Company ), a clinical-stage biopharmaceutical company with a novel immunotherapy...

SAB Biotherapeutics Secures Leadership with New Executive Contracts

SAB Biotherapeutics (SABS) has issued an update. SAB Biotherapeutics, Inc. has entered into new executive employment agreements with Eddie J. Sulli...

Analyzing SAB Biotherapeutics (NASDAQ:SABS) and Shanghai Junshi Biosciences (OTCMKTS:SHJBF)

SAB Biotherapeutics (NASDAQ:SABS  Get Free Report) and Shanghai Junshi Biosciences (OTCMKTS:SHJBF  Get Free Report) are both medical companies, but which is the superior business? We...

SAB Biotherapeutics to Present at the BIO CEO & Investor Conference

SIOUX FALLS, S.D., Feb. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ( SAB or the Company ), a clinical-stage biopharmaceutical company with a novel immunotherapy...

SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

SIOUX FALLS, S.D., Feb. 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ( SAB or the Company ), a clinical-stage biopharmaceutical company with a novel immunotherapy...

SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. It is engaged in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. SAB Biotherapeutics was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Miami Beach, FL.

Volume	2,920.00
52-Wk High	$10.50
52-Wk Low	$2.36

SABS SAB Biotherapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals